SABCS: Omission of Axillary Staging Noninferior for Node-Negative Breast Cancer
FRIDAY, Dec. 13, 2024 -- Omission of surgical axillary staging is noninferior to sentinel-lymph-node biopsy for patients with clinically node-negative, T1 or T2 invasive breast cancer, according to a study published online Dec. 12 in the New England Journal of Medicine to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.
Toralf Reimer, Ph.D., from the University of Rostock in Germany, and colleagues conducted a prospective, randomized, noninferiority trial to examine omission of axillary surgery compared with sentinel-lymph-node biopsy in patients with clinically node-negative breast cancer (stages T1 or T2) who were scheduled to undergo breast-conserving surgery. The primary efficacy outcome was per-protocol analysis of invasive disease-free survival. The five-year invasive disease-free survival rate had to be at least 85 percent to show noninferiority, and the upper limit of the confidence interval for the hazard ratio for invasive disease or death had to be below 1.271.
A total of 5,502 eligible patients were randomly assigned in a 1:4 ratio. The per-protocol population comprised 4,858 patients: 962 were assigned to undergo treatment without axillary surgery (surgery-omission group) and 3,896 were assigned to sentinel-lymph-node biopsy (surgery group). Patients were followed for a median of 73.6 months. The researchers found that the estimated five-year invasive disease-free survival rate was 91.9 and 91.7 percent among patients in the surgery-omission and surgery groups, respectively (hazard ratio, 0.91; 95 percent confidence interval, 0.73 to 1.14), meeting noninferiority.
"The omission of axillary sentinel-lymph-node biopsy does not compromise survival in patients with early-stage, cN0 breast cancer who plan to undergo primary breast-conserving surgery," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
WEDNESDAY, Oct. 1, 2025 -- People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.